Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELECT-A: Pemetrexed, Cisplatin, and Bevacizumab in Stage IV Non-Squamous NSCLC
NCT01674738Phase 2Withdrawn
- Sponsor
- Aktion Bronchialkarzinom
- Modality
- Small Molecules, Monoclonal Antibodies
01
Overview
A Phase 2 trial of pemetrexed, cisplatin, bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Aktion Bronchialkarzinom. Status: withdrawn.
02
Drugs
pemetrexedcisplatinbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01674738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01674738.